The IPO market is starting to regain momentum, with several companies preparing to list on the IDX in the coming weeks. Sucor Sekuritas is acting as the underwriter for two upcoming IPOs, JELI and PRDL. Among the two, PT Prodia Diagnostic Line Tbk (PRDL) stands out by offering exposure to Indonesia's healthcare diagnostics industry, a sector supported by long-term structural growth as demand for healthcare services continues to rise.

What makes PRDL particularly interesting is not only the industry it operates in, but also its strong competitive moat. As a manufacturer of in-vitro diagnostic (IVD) products, the company has spent more than a decade building its manufacturing capabilities, regulatory approvals, and quality certifications—creating high barriers to entry for new competitors. On top of that, PRDL has an exclusive technology partnership with DiaSys (Germany), one of the world's leading IVD companies, enabling it to offer internationally recognized products while maintaining the cost advantages of local manufacturing. This combination positions the company well to benefit from Indonesia's growing preference for domestically produced medical devices.
 

From a financial perspective, PRDL is also entering an attractive phase of its growth journey. The company has largely completed its major capital investment cycle, with most of the heavy spending on production facilities already behind it. Going forward, capital expenditure is expected to be significantly lower and mainly focused on maintenance. As a result, future revenue growth has the potential to translate into stronger operating leverage, allowing earnings to grow at a faster pace as the existing production capacity is further utilized.

The public offering period is scheduled for 1–7 July 2026, with the shares expected to be listed on the IDX on 9 July 2026. As the IPO market becomes more active again, PRDL is one offering worth keeping on the radar, particularly for investors seeking exposure to Indonesia's healthcare sector through a company with solid fundamentals, meaningful competitive advantages, and long-term earnings growth potential.